Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.68 |
| ▸ | HTR3B | O95264 | 5/20 | 0.68 |
| ▸ | HTR3A | P46098 | 5/20 | 0.68 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404203 | 0.82 | HRH4 (1.00) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| Hydrochloric Acid SCHEMBL29694104 | 0.80 | HRH4 (0.97) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL14828911 | 0.80 | HRH4 (0.52) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL14828829 | 0.77 | HRH4 (0.56) | HRH4HTR3BHTR3ASMN1; SMN2 | |
| SCHEMBL29268331 | 0.77 | HRH4 (0.88) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL15567148 | 0.76 | GPR6 (0.69) | HTR3BHTR3AHTR3EHTR3DHTR3C | |
| SCHEMBL14828844 | 0.76 | HRH4 (0.55) | HRH4HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL14828756 | 0.75 | HRH4 (0.54) | HRH4HTR3BHTR3ASMN1; SMN2 | |
| SCHEMBL14828796 | 0.75 | HRH4 (0.54) | HRH4HTR3BHTR3ASMN1; SMN2 | |
| SCHEMBL15567603 | 0.75 | GPR6 (0.72) | HTR3BHTR3AHTR3EHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3461825-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2019-04-03 | — | — | EP | disclosed |
| EP-2760865-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2018-07-11 | — | — | EP | disclosed |
| US-9586959-B2 | Substituted tricyclic heterocycles as histamine 4 receptor inhibitors | C&C RESEARCH LABORATORIES (KR) | 2017-03-07 | — | — | US | disclosed |
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2014-10-23 | — | — | US | disclosed |
| EP-2760865-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013048214-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | HRH4, HRH2, HRH1 | HRH4 1/4885HTR3B 452/4885HTR3A 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.